4.7 Meeting Abstract

Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN plus etoposide (ETP) plus ifosfamide (IFM) in patients (pts) aged 2 to ≤25 years with relapsed/refractory osteosarcoma (OS).

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 36, Issue 15, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2018.36.15_suppl.11527

Keywords

-

Categories

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available